Maximize Your Drug Design Possibilities with RenNano-derived Fully Human Nanobodies
Speaker: Yi (Benny) Yang, PhD.
Chief Scientific Officer, Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Compared to traditional antibodies, nanobodies are significantly smaller in size, which is advantageous for penetrating tumors and crossing the blood-brain barrier. The protruding CDR3 regions of nanobodies make them better at targeting hidden epitopes, and their simple structure makes them ideal for assembly into bispecific/multispecific antibodies or CAR proteins for cell therapy. To overcome the difficulties of discovering nanobodies from natural nanobody-producing species (e.g., camel, shark), Biocytogen genetically engineered RenNano® mice to produce fully human heavy chain-only antibodies (HCAbs). RenNano-derived HCAbs exhibit sequence diversity, optimal affinity, superb hydrophilicity, suitable thermostability and favorable PK properties. In our first webinar in the new year, Dr. Yi (Benny) Yang outlined the current landscape of nanobody-based therapeutics, introduced the capability of the RenNano platform with case study examples, and described Biocytogen’s “Nano 100 Project”, designed for large-scale nanobody discovery.
